《新股表現》三葉草(02197.HK)上市翌日 股價隨疫苗股急挫29%
美國兩大藥廠默克(MRK.US)及輝瑞(PFE.US)先後研發新冠口服藥臨牀試驗療效顯着,可大幅降低住院和死亡風險。市場憂慮新冠疫苗需求下降,本港上市疫苗股全面捱沽,三葉草生物-B(02197.HK)上市翌日,股價繼上週五較上市價13.38元反覆低3%後,今天跌勢轉急,最低見9.16元新低,現報9.21元,急瀉29%,成交414萬股。
內地三葉草生物是一家處於臨牀試驗階段全球性生物技術公司,致力於爲傳染性疾病與癌症及自身免疫性疾病開發的新型疫苗及生物治療候選產品。公司主要產品於各治療領域適應症分別爲COVID-19、惡性腹水及強直性脊柱炎。此外,公司已開發另一款核心產品SCB-808,用於治療風溼性疾病。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.